# Clinical Outcomes of an Innovative Poly‐L‐Lactic Acid (LASYNPRO) in Facial Rejuvenation: Prospective, Multicenter Spanish Study

## TL;DR

A new facial rejuvenation treatment using Poly-L-lactic acid (PLLA LASYNPRO) showed lasting improvements in wrinkles and volume with high patient satisfaction and minimal side effects.

## Contribution

Demonstrates the clinical efficacy and safety of PLLA LASYNPRO for facial rejuvenation with biological evidence of collagen stimulation.

## Key findings

- PLLA LASYNPRO significantly improved wrinkle severity and midface volume over six months.
- Patient satisfaction remained high, with most reporting 'Much Better' or 'Better' results.
- Biological markers and imaging confirmed collagen stimulation and improved skin properties.

## Abstract

To evaluate the clinical efficacy, patient satisfaction, safety profile, and biological impact of Poly‐L‐lactic acid (PLLA LASYNPRO) over 6 months.

This prospective, multicenter study included patients treated with PLLA‐LASYNPRO. The primary end‐point was the proportion of participants who achieved a reduction of at least 1 point in the Wrinkle‐Severity‐Rating‐Scale (WSRS). Secondary end‐points included the proportion of participants achieving at least a 1‐point reduction in the Midface‐Volume‐Deficit‐Scale (MFVDS), the degree of patient satisfaction assessed by the Global‐Aesthetic‐Improvement‐Scale (GAIS), treatment‐related biological and structural changes, and the incidence of adverse events (AEs).

Thirty‐six female subjects were enrolled. Right‐side treatment success rates increased from 44.4% at month‐1 to 71.9% at month‐6 (Cochran's Q, p = 0.005); left‐side rates increased from 44.4% to 68.8% (p = 0.006). MFVDS‐treated‐side success increased significantly (44.4% to 65.6%; p = 0.004). GAIS ratings of “Much Better” or “Better” were reported by 66.7% at month 1 and remained high (65.6% at month‐6). Ultrasound and elastography imaging confirmed increased tissue density, reduction of the Sub‐Epidermal‐Low‐Echogenic‐Band (SLEB), signs of neocollagenesis, and improved viscoelasticity. Serum P1CP levels rose significantly from 134.6 ± 98.9 ng/mL to a peak of 233.2 ± 163.1 ng/mL at month 2 (p < 0.001 vs. baseline), remaining elevated through month 6 (p = 0.012). AEs were limited to mild–moderate, self‐resolving inflammation, erythema, edema, and injection‐site discomfort; no serious AEs occurred.

PLLA‐LASYNPRO achieved significant, sustained improvements in facial wrinkles and volume with high patient satisfaction and biological evidence of collagen stimulation. The treatment demonstrates an excellent safety profile. Further large‐scale, randomized trials are recommended to confirm long‐term efficacy and define its role in aesthetic practice.